Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.
Most patients with primary central nervous system (CNS) lymphoma or systemic non-Hodgkin's lymphoma (NHL) involving the CNS relapse after an initial response to treatment, often presenting with leptomeningeal disease. Since the majority of these lymphomas are B-cell neoplasms expressing the CD20 surface antigen treatment with the chimeric monoclonal antibody (Mab) rituximab might be a new therapeutic option. Here, we report on 6 patients with relapsed CNS B-cell lymphoma who were treated with intraventricular or intrathecal applications of rituximab. One of these cases has already been reported.
Schulz
Holger
H
Pels
Hendrik
H
Schmidt-Wolf
Ingo
I
Zeelen
Ulrich
U
Germing
Ulrich
U
Engert
Andreas
A
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D006801:Humans; D007276:Injections, Intraventricular; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008577:Meningeal Neoplasms / Q000188:drug therapy; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab